Managers / Q1 2024 · view latest →
Propel Bio Management, LLC
CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629
Summary
Propel Bio Management, LLC reported $172M in U.S.-listed holdings across 29 positions for Q1 2024.
The portfolio is heavily concentrated: APLT alone accounts for 24.2% of reported value.
Compared with Q4 2023, the fund opened 4 new positions and exited 10.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 78.2% · $134M
- ETP · 17.8% · $31M
- Other · 3.2% · $5M
- Closed-End Fund · 0.9% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SP4PACHIEVE LIFE SCIENCES INC | NEW | +2.45M | 2.45M | +$11M | $11M |
| SNDXSYNDAX PHARMACEUTICALS INC | NEW | +83.3K | 83.3K | +$2M | $2M |
| TRVITREVI THERAPEUTICS INC | NEW | +260.0K | 260.0K | +$897,000 | $897,000 |
| 72CEIGER BIOPHARMACEUTICALS INC | NEW | +146.4K | 146.4K | +$731,905 | $731,905 |
| SIMPLIFY ENHANCED INCOME | ADDED | +1.37M | 1.49M | +$25M | $28M |
| AKROAKERO THERAPEUTICS INC | ADDED | +227.7K | 327.8K | +$6M | $8M |
| PAGPEURPLAINS GP HOLDINGS LP-CL | SOLD OUT | −1.37M | 0 | −$22M | $0 |
| CRNXCRINETICS PHARMACEUTICALS IN | SOLD OUT | −165.0K | 0 | −$6M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $159M | 38 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $117M | 20 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $100M | 16 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 16 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $86M | 18 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $101M | 21 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $172M | 21 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $154M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $172M | 29 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 34 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Simplify Asset Management Inc.028-20937
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.